ArticleJMIR medical informatics2025
Model for Predicting Serious Hematological Adverse Events in Individuals With Ovarian Cancer Receiving Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Treatment: Prospective Cohort Study.
Article in JMIR medical informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPredicting serious hematological adverse events (SHAEs) from poly (adenosine diphosphate ribose) polymerase inhibitors (PARPis) would allow us to prioritize patients with ovarian cancer at higher risk for more intensive care, ultimately lowering morbidity and preventing them from premature termination of medication.
objectiveThis study aimed to explore the risk factors for SHAEs in patients with ovarian cancer receiving PARPi treatment and develop a risk prediction model for such events.
methodsProspective clinical data were collected on patients with ovarian cancer who received PARPi treatment at the Guangxi Medical University Affiliated Tumor Hospital from December 2018 to August 2024. They were divided into a SHAE group and a no-SHAE group based on the occurrence of SHAEs. Variable differences were screened using the chi-square test or Fisher exact test. Multivariate logistic regression was used to determine independent factors influencing SHAEs in patients with ovarian cancer. A predictive model for serious blood-related complications in ovarian cancer treatment was developed from identified independent risk factors using the R software. The model's clinical utility was assessed through decision curve analysis (net benefit), calibration (calibration curve), and discrimination (receiver operating characteristic curve).
resultsA total of 70 patients with ovarian cancer receiving PARPi treatment were included in this study. Of these 70 patients, 16 (23%) experienced SHAEs, with decreases in red blood cell (RBC) count and hemoglobin levels being the most common. Multiple logistic regression analysis identified 4 independent predictors of PARPi-associated SHAEs in patients with ovarian cancer: lymph node metastasis (odds ratio [OR] 6.733, 95% CI 1.197-37.873; P=.03), creatinine clearance rate of ≤60 mL per minute (OR 23.722, 95% CI 3.121-180.303; P=.002), RBC count of ≤3.3×10
conclusionsLymph node metastasis, creatinine clearance rate of ≤60 mL per minute, RBC count of ≤3.3×10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.